Viewing Study NCT04276220


Ignite Creation Date: 2025-12-25 @ 4:24 AM
Ignite Modification Date: 2025-12-26 @ 3:27 AM
Study NCT ID: NCT04276220
Status: COMPLETED
Last Update Posted: 2025-08-15
First Post: 2020-02-18
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: Prevalence of wtATTR-CM After Carpal Tunnel Release Surgery
Sponsor: Steen Hvitfeldt Poulsen
Organization:

Study Overview

Official Title: Prevalence of Wild-Type Transthyretin Cardiac Amyloidosis Among Patients Undergoing Carpal Tunnel Release Surgery - A Prospective Study
Status: COMPLETED
Status Verified Date: 2025-08
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: CACTuS2
Brief Summary: Patients above the age of 60 will be recruited at their carpal tunnel release surgery. Biopsies will be taken from the wrist and examined for the presence of amyloid protein. A amyloid-positive biopsy will refer the patients for cardiac examination including blod- and urine samples examined for transthyretin.

If the result of the cardiac examination is suspected cardiac amyloidosis, the patient will be referred for a diagnostic TC99-DPD scintigraphy. If the scintigraphy is positive, the patient will be referred for right heart catherization (RHC) and an exercise test.

Myocardial biopsies will be taken at the RHC and examined with electron microscopy and high resolution respirometry.
Detailed Description: None

Study Oversight

Has Oversight DMC: True
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: False
Is an FDA AA801 Violation?: